Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04748848
Ignite Creation Date: 2024-05-06 @ 3:46 PM
Last Modification Date: 2024-10-26 @ 1:56 PM
Study NCT ID: NCT04748848
Protocol Section: NCT04748848
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Safety Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in RR Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Official Title: A Phase 12 Open-label Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in RR Acute Myeloid Leukemia AML and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy
Acronym: None
Organization: Celgene
Organization Class: INDUSTRY
Organization Study ID: CC-90011-AML-002
Secondary IDs
Secondary ID Type Domain Link
U1111-1251-6973 REGISTRY None None
2020-005341-16 EUDRACT_NUMBER WHO None
Start Status Module Data
Status Verified Date: 2023-02
Overall Status: TERMINATED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Celgene
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Celgene
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload